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Background: Despite a growing consensus that biofilms contribute to a delay in
the healing of chronic wounds, conflicting evidence pertaining to their
identification and management can lead to uncertainty regarding treatment. This,
in part, has been driven by reliance on in vitro data or animal models, which may
not directly correlate to clinical evidence on the importance of biofilms. Limited
data presented in human studies have further contributed to the uncertainty.
Guidelines for care of chronic wounds with a focus on biofilms are needed to help
aid the identification and management of biofilms, providing a clinical focus to
support clinicians in improving patient care through evidence-based medicine.
Methods: A Global Wound Biofilm Expert Panel, comprising 10 clinicians and
researchers with expertise in laboratory and clinical aspects of biofilms, was
identified and convened. A modified Delphi process, based on published scientific
data and expert opinion, was used to develop consensus statements that could help
identify and treat biofilms as part of the management of chronic nonhealing
wounds. Using an electronic survey, panel members rated their agreement with
statements about biofilm identification and treatment, and the management of
chronic nonhealing wounds. Final consensus statements were agreed on in a face-
to-face meeting. Results: Participants reached consensus on 61 statements in the
following topic areas: understanding biofilms and the problems they cause
clinicians; current diagnostic options; clinical indicators of biofilms; future options
for diagnostic tests; treatment strategies; mechanical debridement; topical
antiseptics; screening antibiofilm agents; and levels of evidence when choosing
antibiofilm treatments. Conclusion: This consensus document attempts to clarify
misunderstandings about the role of biofilms in clinical practice, and provides a
basis for clinicians to recognize biofilms in chronic nonhealing wounds and
manage patients optimally. A new paradigm for wound care, based on a stepped-
down treatment approach, was derived from the consensus statements.
EXECUTIVE SUMMARY
A wound that is not healing in a timely fashion, despite
holistic investigation and optimal intervention, can
be considered as being chronic. Interventions may include
treatment of infection, maintenance debridement,
adequate compression (venous leg ulcers), restoration of
arterial inflow (ischemic ulcers), adequate attention and
intervention with respect to pressure injury (PI), offload-
ing in diabetes-related foot ulcers (DRFUs), and manage-
ment of other factors or underlying systemic diseases.
After controlling for these factors, biofilms are probably
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the most important single cause of persistent, delayed
healing.1–4
Data about incidence, susceptibility, and treatment of
biofilms derived from experimental animal models5–8 and
in vitro studies9,10 have helped shape general concepts
about detecting and treating biofilm bacteria, but there are
limits to the extent this information can be extrapolated to
clinical management. The clinical evidence base is poor,
with limited human studies and few controlled trials that
provide scientifically acceptable data to inform clinical
management.3,11–14 Despite publication of several treat-
ment algorithms,15,16 there is little published clinical data
to confirm that following algorithm-guided care improves
wound healing over standard care. Furthermore, there is
wide disparity in clinicians’ knowledge of research data
that are available and the importance of biofilms in the
management of chronic, nonhealing wounds.
Failure to recognize the adverse influence of biofilms
can result in suboptimal treatment of chronic wounds.
Current guidelines published by the European Society of
Clinical Microbiology and Infectious Disease (ESCMID)
Study Group for Biofilms (ESGB) have provided a strong
platform for recommendations regarding the management
of medically related biofilms.3 However, these guidelines
only briefly address the issue of biofilm involvement in
chronic nonhealing wounds. To remedy this situation, the
link from research studies to clinical practice (e.g., “bench
to bedside”) needs to be approached in a systematic, clear,
and unbiased way. This would aid clinicians in clarifying
optimal treatment strategies. An expert panel was con-
vened in 2015 to improve understanding of best practices
in wound care. The goal was to develop consensus state-
ments for the identification and management of biofilms,
drawing on the scientific literature, and the clinical and
research experience of the panel members. The final con-
sensus statements, along with the supporting evidence, are
presented for 10 key topic areas. A subset of the 10 most
essential (key) statements is listed in Table 1. Importantly,
a new paradigm for wound care based on a stepped-down
approach is presented (Figure 2).
METHODS
Panelists
A mapping process was conducted to identify panelists,
who were selected on the basis of their peer-reviewed pub-
lications, scholarly activity, and reputation as an expert in
chronic wounds and impact of biofilm. Diversity among
panel members was sought in their geographical practices,
clinical specialties, and both clinical or research activities.
Ten experts (US, four; UK, two; Australia, two; Denmark,
one; Japan, one) participated.
Modified Delphi process and scoring of agreement
A modified Delphi method17 was used because it is a
well-recognized and validated means of reaching
Table 1. Key consensus statements
 Wounds that contain biofilms may not be identified, resulting in ineffective treatment and delayed healing [strong
agreement, mean 4.3, SD 0.82].
 Biofilms are present in most chronic wounds [strong agreement, mean 4.8, SD 0.42], and are likely to be located both on
the surface and in deeper wound layers, but may not be present uniformly across or within the wound [strong agreement,
mean 4.5, SD 0.97].
 Wound biofilms are difficult to visualize macroscopically and slough, debris, and exudate may be visually mistaken for biofilm
by clinicians/healthcare professionals [strong agreement, mean 4.6, SD 0.73].
 Important indicators that a wound is likely to contain a biofilm include recalcitrance to treatment with antibiotics or antisep-
tics [strong agreement, mean 4.3, SD 0.67].
 The most important measure for future diagnostic tests to consider is indication of where the biofilm is located within the
wound [strong agreement, mean 4.0, SD 0.82].
 Debridement is one of the most important treatment strategies against biofilms, but does not remove all biofilm, and there-
fore cannot be used alone—this is one of the critical principles of wound bed preparation (tissue, infection/inflammation,
moisture balance, and edge of wound) [strong agreement, mean 4.9, SD 0.32].
 Biofilms can reform rapidly; repeated debridement alone is unlikely to prevent biofilm regrowth; however, effective topical
antiseptic application within this time-dependent window can suppress biofilm reformation [strong agreement, mean 4.0,
SD 0.67].
 Topical antiseptics that are effective antibiofilm treatments should have strong antibiofilm effects in appropriate in vitro test
models against mature biofilms [strong agreement, mean 4.0, SD 0.67].
 In vitro biofilm methods with clinically relevant test conditions are useful to screen treatments for their antibiofilm efficacy
[strong agreement, mean 4.5, SD 0.71].
 RCTs and comparative clinical evidence of antibiofilm treatment should be used to support clinical guidelines, protocols, and
treatment choices. However, in the absence of RCT-level data, antibiofilm interventions should be supported by RCT
evidence of the broader impact on wound healing [strong agreement, mean 4.2, SD 0.79].
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consensus on debatable clinical issues,18 particularly when
scientifically acceptable clinical evidence is lacking. To
begin the process, the panel elected to address 10 topic
areas considered to be important for the management of
chronic nonhealing wounds: (1) problems biofilms cause
clinicians, (2) understanding biofilms, (3) current diagnos-
tic options for biofilms, (4) clinical indicators of biofilms,
(5) future options for diagnostic tests, (6) biofilm treatment
strategy, (7) mechanical debridement, (8) topical antisep-
tics, (9) screening antibiofilm agents, and (10) levels of
evidence when choosing antibiofilm treatment. A detailed
description of the Delphi process is presented in Support-
ing Information Figure S1.
A series of statements was formulated to address impor-
tant aspects in each of these areas and distributed to panel
members electronically (round 1 of the modified Delphi
process). Regardless of statement type, panelists used their
knowledge of publications in this field and/or clinical
experience to guide their scoring or ranking. Statements
for which consensus was not achieved were reformulated
and circulated electronically and anonymously in round 2
of the modified Delphi process, along with the overall
score for each statement, so each respondent could identify
where their score lay in comparison. Any remaining areas
where there was a lack of consensus were then addressed
during extensive discussion in a face-to-face meeting at
which final consensus statements were formulated and
agreed upon. The final published statements listed in the
text of this manuscript have, in some cases, been modified
and/or consolidated by the panel after face-to-face discus-
sion and therefore may not completely correspond to the
statements from the original round of the Delphi process.
Therefore, some statements do not have mean scores asso-
ciated with them and are so designated by the following
text: “Full panel agreement at final meeting.” The panel
agreed on a total of 61 consensus statements, grouped into
10 general topic areas. A list of key consensus statements
is provided in Table 1. Statements for which consensus
was not reached during the Delphi process are listed in
Supporting Information Table S1.
CONSENSUS STATEMENTS
Problems biofilms cause clinicians
Key statement: (1) Wounds that contain biofilms may
not be identified, resulting in ineffective treatment and
delayed healing [strong agreement, mean 4.3, SD 0.82].
(2) Ineffective biofilm treatment leading to delayed
healing results in a decrease in patient quality of life
and can put an additional burden on healthcare resour-
ces [strong agreement, mean 4.7, SD 0.67].
(3) Lack of biofilm knowledge is a critical barrier to
effective management of wounds that contain biofilms
[strong agreement, mean 4.0, SD 0.82].
(4) Ineffective biofilm treatment leading to delayed
healing can put an additional burden on healthcare
resources [strong agreement, mean 4.7, SD 0.67].
Evidence summary
Although some indirect (surrogate) features on the surface
of wound beds (e.g., extensive fibrinous slough) that are
indicative of biofilm may be visible to the naked eye,19 in
many cases, the actual biofilms are located in the deeper
tissue layers in the wound bed (e.g., an average depth of
50–70 microns20), creating issues with diagnosis. The
inability to discriminate between slough and biofilm, and
to reliably determine the presence of biofilm using clinical
cues, may result in suboptimal care.11 Having no definitive
biomarkers or clinical cues that are available or used by
clinicians compounds this further.
Furthermore, clinicians must be aware that treatment
protocols based on planktonic paradigms of acute infec-
tions are not appropriate for chronic nonhealing wounds
complicated by biofilms. One example of the difference
between planktonic and biofilm phenotypes is the inherent
tolerance of biofilms to many forms of treatment that
include both systemic antibiotics and topical
antiseptics.21–28
Understanding biofilms
Key statement: (1) Biofilms are present in most
chronic wounds [strong agreement, mean 4.8, SD 0.42],
and are likely to be located both on the surface and in
deeper wound layers, but may not be present uniformly
across or within the wound [strong agreement, mean
4.5, SD 0.97].
(2) The presence of biofilms and the response to them
are associated with delayed wound healing [strong
agreement, mean 4.5, SD 0.71].
(3) Biofilms in chronic wounds are likely to be more
established or mature [strong agreement, mean 4.3,
SD 0.82].
(4) The biofilm structure may promote the presence of
anaerobic bacteria [strong agreement, mean 4.3,
SD 0.82].
(5) The microbiota of chronic wounds is often polymi-
crobial; however, wound biofilms may consist of single
or multiple bacterial species [strong agreement, mean
4.3, SD 0.82].
(6) Microbial diversity in a wound (planktonic and bio-
films) can be influenced by location and wound charac-
teristics [full panel agreement at final meeting].
(7) Biofilms in wounds may progress to contain fewer,
more dominant species over time but more research is
needed to verify this [full panel agreement at final
meeting].
(8) Biofilms are more tolerant to the host immune
response and can evade phagocytosis due to community
defenses [full panel agreement at final meeting].
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(9) Microbial diversity in a wound can be influenced by
location and wound characteristics but not necessarily
wound type [full panel agreement at final meeting].
Evidence summary
There is increasing evidence that biofilms are present in
most, if not all, chronic nonhealing wounds.19 A recent
meta-analysis of in vivo studies highlights that at least 78%
of chronic wounds contain a biofilm.29 However, the small
size and heterogeneous distribution of biofilms,30,31 in con-
junction with the finding that microorganisms in biofilms
are not only located at the wound surface but may also be
present in deeper tissues,32 can explain why, when cultured,
some wounds produce a false-negative result, in spite of
overwhelming clinical features suggestive of wound biofilm.
Figure 1 illustrates various aspects of biofilms associated
with biopsies taken from chronic wounds. Although we dis-
cuss wounds as being infected with biofilm or not, in real-
ity, it is likely that there is a ratio between planktonic and
biofilm, as seen in animal models, and the relative contribu-
tion of each for any given wound can influence the efficacy
of a treatment. However, if any biofilm is present, there is
potential for persistent or recurrent infection.
The exact mechanisms by which biofilms can delay
wound healing are still the subject of much scientific inves-
tigation. Virtually all evidence has come from either in vitro
or animal models, where experimental conditions can be
controlled.32–38 Unfortunately, no large clinical studies have
confirmed this. Nevertheless, biofilms have been demon-
strated to play a detrimental role in many chronic diseases,
such as cystic fibrosis39–44 and sinusitis,43–46 and may com-
promise in-dwelling medical devices.47
The contribution of biofilms to the pathogenesis of
chronic wounds is shown in Supporting Information
Figure S2. Biofilms are also thought to delay wound healing
by eliciting an inappropriate inflammatory response, which
is ineffective and poorly orchestrated, and damaging to host
tissues.16,48–51 A recent experiment in mice highlighted the
ability of the microbiota (including biofilm) taken from
chronic human wounds to elicit signs of chronic infection
when transplanted into wounds on mice.52
An important contributor to the persistence of biofilms
is that the biofilm matrix protects contained bacteria from
systemically administered antibiotics and topical antisep-
tics, antibodies, complement, and phagocytosis.53–57 Neu-
trophils not only have difficulty penetrating an intact
biofilm: they are also unable to effectively engulf large
biofilm communities. Furthermore, biofilms within a
wound may vary in maturity but, once mature, biofilms
are more likely to be tolerant to both antibiotics and anti-
septics than biofilms still in the process of maturation.58
Regarding bacterial and biofilm diversity, the applica-
tion of molecular techniques using DNA sequencing
(amplification and sequence analysis of the 16S rRNA
gene) has provided improved knowledge of the chronic
wound microbiome and the microorganisms involved in
biofilm infections. One such study of 2,963 patients with
various chronic wounds (e.g., PI, diabetic foot ulcers,
venous ulcer, and dehisced nonhealing surgical incisions)
reported that Staphylococcus and Pseudomonas comprise
the most prevalent genera present in the microbiota of
chronic wounds, but also highlighted the high prevalence
of anaerobic bacteria. Interestingly, the bacterial composi-
tion was not related to wound type.59
Figure 1. Microscopy images demonstrating key features of
wound biofilms. (A) Peptide nucleic acid-based fluorescent in
situ hybridization (PNA-FISH) analysis from diabetic foot
ulcer with suspected biofilm involvement. Image courtesy of
Matthew Malone. (B) Scanning electron micrograph (SEM)
of chronic wound. Image courtesy of Matthew Malone. (C)
PNA-FISH with confocal laser scanning microscopy (CLSM)
for bacteria (eubacterial probe [green] and Pseudomonas aer-
uginosa probe [red]) surrounded by inflammatory cells (DAPI
[blue]) located deep within the tissue. Image courtesy of
Thomas Bjarnsholt. (D) CLSM for bacterial matrix (antibody
stain against P. aeruginosa alginate [red, 1]) showing matrix
enclosed bacteria located deep within the tissue. Image
courtesy of Thomas Bjarnsholt. (E) CLSM cross-section of
thick biofilm (SYTOX [green, 1]) on wound surface tissue
(propidium iodide [red, 2]). Image courtesy of Randall D.
Wolcott, Garth A. James, and Steven T. Fisher.
Schultz et al. Guidelines for chronic wound biofilms
Wound Rep Reg (2017) 25 744–757 VC 2017 by the Wound Healing Society 747
Aerobic bacteria in the biofilm, by virtue of their con-
sumption of tissue oxygen, create a conducive environment
that can promote the proliferation of anaerobes in the extra-
cellular polymeric substances (EPS). Oxygen gradients have
been demonstrated in vitro, in murine models, and in human
clinical specimens.60 The metabolism and respiratory burst
of leukocytes within the wound may also deplete oxygen
and, in a mouse model, Pseudomonas aeruginosa were
shown to experience oxygen-limitation stress.60
Current diagnostic options for biofilms
(1) There are currently no routine diagnostic tests
available to confirm biofilm presence [strong
agreement, mean 4.7, SD 0.48].
Key statement: (2) Wound biofilms are difficult to visual-
ize macroscopically and slough, debris, and exudate may
be visually mistaken for biofilm by clinicians/healthcare
professionals [strong agreement, mean 4.6, SD 0.73].
(3) Tissue biopsies are more reliable than swabs to
reveal biofilms in wounds. However, routine culture
techniques do not necessarily identify biofilm presence,
and specialist knowledge of biofilm culture is required
[strong agreement, mean 4.2, SD 0.63].
(4) In the absence of bedside diagnostic tests, specific
signs and symptoms should be used to confirm biofilm
presence [strong agreement, mean 4.0, SD 0.82].
Evidence summary
It is unlikely that aggregates in wound biofilms can be
visualized with the naked eye, since they are often less
than 100 lm and have no macroscopically distinguishable
features.1 Recent guidelines on medically related biofilms
by the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) biofilm study group
(ESGB)3 stated that approaches such as the use of scan-
ning electron microscopy (SEM) and confocal laser scan-
ning microscopy (CLSM) are the most reliable types of
diagnostic techniques. SEM, for example, can identify bio-
films in wounds not showing evidence of acute infection.19
However, these imaging techniques are highly specialized
and not practical in a typical clinical setting.
Sampling methods may also cause variable diagnosis; a
wound swab may pick up biofilms located on the wound
surface, but may fail to isolate large amounts of biofilm-
Figure 2. Summary of the step-down/step-up approach to biofilm-based wound care.
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related bacteria in deeper tissues. Consequently, this
method has poor sensitivity and specificity, and biofilms
may be present in wounds with negative or positive culture
reports.61 Similarly, the heterogeneous distribution of bio-
film across a wound means that single biopsies may also
miss the biofilm during sampling1,12,62; however, they do
sample both surface and deeper tissue. As a result, many
expert groups advocate curettage samples, punch biopsies,
and other samples from sharp debridement containing
wound tissue as the gold standard method for identifying
pathogens in biofilm infection.63,64
Clinical indicators of biofilms
(1) There are clinical signs and symptoms that
clinicians can use to infer the presence of biofilm in a
wound (even in the absence of traditional clinical signs
of infection) [weak agreement, mean 3.6, SD 1.5].
(2) Important indicators that a wound is likely to
contain a biofilm include:
Key statement: (2.1) Recalcitrance to treatment
with antibiotics or antiseptics [strong agreement,
mean 4.3, SD 0.67].
(2.2) Treatment failure despite using appropriate
antibiotics or antiseptics [strong agreement, mean
4.0, SD 0.67].
(2.3) Delayed healing [weak agreement, mean 3.9,
SD 0.99].
(2.4) Cycles of recurrent infection/exacerbation
[weak agreement, mean 3.8, SD 0.79].
(2.5) Excessive moisture and wound exudate
[weak agreement, mean 3.5, SD 1.51].
(2.6) Low-level chronic inflammation [weak agree-
ment, mean 3.4, SD 0.97].
(2.7) Low-level erythema [weak agreement, mean
3.1, SD 0.74].
Evidence summary
It has been proposed that the presence of biofilm in
wounds can be inferred by routine clinical assessments,
including excessive moisture, poor quality granulation tis-
sue, signs of local infection, history of antibiotic failure,
culture-negative results despite signs of clinical infection,
and failure to heal after addressing comorbidities.15 Other
authors have proposed that visual cues can be used by the
clinician to guide the suspicion of the presence of wound
biofilm, which can be enhanced with the use of a clinical
algorithm.19 Clinical indicators for the presence of wound
biofilm presented the weakest agreement for consensus
between panel members. Fibrin and slough are often mis-
taken for biofilm EPS and viewed as an indicator of
biofilm. When exploring this concept, the panel proposes
that slough is frequently a combination of plasma proteins,
especially fibrin, partially degraded extracellular matrix
proteins, like collagen, and devitalized tissue, which may
support attachment of planktonic bacteria and subsequent
biofilm development.65 Therefore, slough should not be
considered as consisting exclusively of living biofilm, but
slough may often be a surrogate, “downstream” indicator
of inflammation, which may be due in many cases to the
presence of biofilm.
In the absence of sensitive and specific point-of-care
diagnostic tests, a number of clinical features have been
proposed as surrogate markers of a biofilm when a wound
is not healing despite optimal standards of care. These
include the failure of wounds to respond to appropriate
systemic antibiotic or local antiseptic therapy in the pres-
ence of culture-guided selection; wounds that exhibit flares
and quiescent periods with respect to inflammation and
infection; wounds that have high levels of exudate relating
to inappropriate inflammation that stimulates increased
capillary permeability; gelatinous material on the wound
edge that reforms quickly after removal; and mechanical
curettage being needed for removal.3,12,66
Delayed wound healing may also be related to issues
not exclusive to biofilms: sub-therapeutic dose of antibiot-
ics; not meeting minimal inhibitory concentration due to
inadequate perfusion (especially in people with ischemic
limbs); repeated trauma due to inadequate offloading;
incorrect dressing regimens and lack of compression ther-
apy; and/or poor patient compliance with any current or
previous culture-directed systemic antibiotic therapy. Thus,
the usefulness of delayed healing as an indicator of biofilm
is only likely when the “standard of care” has failed. The
panel proposes that clinicians should assume that all
chronic wounds that exhibit delayed healing despite opti-
mal standards of care should be regarded as having biofilm
present.
Future options for diagnostic tests
(1) The most important measures for future diagnostic
tests to consider are:
(1.1) Differentiate whether the bacteria in the wound
are biofilm or planktonic [strong agreement, mean
4.6, SD 0.52].
(1.2) Identification of which species of bacteria are
present [strong agreement, mean 4.6, SD 0.52].
(1.3) Identification of the dominant species in the
biofilm [strong agreement, mean 4.0, SD 1.5].
Key statement: (1.4) Indication of where the bio-
film is located within the wound [strong agreement,
mean 4.0, SD 0.82].
(2) The primary point of future diagnostics is to
determine the threshold point above which wounds
do not heal [full panel agreement at final meeting].
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(3) New tests will need clear clinical evidence and
validation [full panel agreement at final meeting].
Evidence summary
The heterogeneous distribution of biofilms in a wound,58
and presence in both deeper and surface tissue,31 poses the
biggest challenge and opportunity for biofilm diagnosis. A
diagnostic that could accurately locate pockets of biofilm
would be advantageous to guide sampling and treatment.
The search for diagnostic markers is made more difficult
considering that wound biofilms can contain a wide variety
of species and many are polymicrobial. Tests that detect
the components of EPS can distinguish between planktonic
and biofilm bacteria, but this would not necessarily iden-
tify the organisms responsible for any delay in healing.
Identification of the dominant species in a biofilm may
also be helpful and allow targeted therapeutics. However,
research is also showing that the less dominant species
may influence the pathogenicity of other species present,
and therefore should not be overlooked.67 Less prevalent
species could also be more virulent and have a greater
contribution to delayed healing. In addition there is some
evidence to suggest that polymicrobial biofilms have
higher virulence compared to single species biofilms.68,69
The predominant microorganism(s) may also change once
therapy targeting a particular species is initiated. Further
challenges are recognized in that bacteria in biofilms also
have an extremely low rate of metabolism, which adds to
the complexity in detection compared to fast growing
planktonic cultures.70
Biofilm treatment strategy
(1) Biofilms should be considered in the treatment of
poorly healing burns [strong agreement, mean 4.3,
SD 0.67].
(2) Antibiofilm strategies should continue to be used
until the wound bed is visibly clean, displaying healthy
granulation tissue, and/or on a healing trajectory [strong
agreement, mean 4.4, SD 0.7].
Key statement: (3) Debridement is one of the most
important treatment strategies against biofilms, but does
not remove all biofilm, and therefore cannot be used
alone—this is one of the critical principles of wound
bed preparation (tissue, infection/inflammation, moisture
balance, and edge of wound) [strong agreement, mean
4.9, SD 0.32].
(4) Systemic antibiotics cannot eradicate a wound bio-
film; therefore, antibiotic stewardship must be consid-
ered with controlled use to help manage planktonic
bacteria, acute infection, and prevention of associated
systemic infections [full panel agreement at final
meeting].
(5) When considering topical antiseptics, those that
are known to have antibiofilm properties are preferred
[strong agreement, mean 4.6, SD 0.52].
(6) Prevention and treatment of biofilms should be
considered in early surgical wounds when there is a
high risk of surgical site infection and dehiscence (open
colorectal surgery, cesarean section, and major joint
replacement serve as examples) [full panel agreement
at final meeting].
(7) Biofilm treatments may be aligned across different
types of chronic wounds, as similar dominant microflora
are usually implicated—assuming the wound-specific
factors are addressed with other treatment strategies
[full panel agreement at final meeting].
Evidence summary
All chronic nonhealing wounds in general require the same
core elements of biofilm-based treatment in their manage-
ment following attention and correction of associated sys-
temic pathologies. Wound care principles should optimize
wound bed preparation with respect to tissue, infection/
inflammation, moisture balance, and edge-of-wound
principles,71,72 and chronic, nonhealing, wounds should be
followed closely to monitor progress. These general
principles have at times been conceptualized with the acro-
nyms TIME73 and DIME.74,75 Additional wound-specific
management should ensure that principles for different
types of wounds are addressed. These include offloading
for diabetic foot ulcers, pressure redistribution for PI,
compression for venous leg ulcers, and adequate attention
to perfusion in ischemic ulcers.
A wound cannot progress to healing when large amounts
of necrotic tissue, exudate, and biofilm are present.76 The
components of biofilm, intracellular, and planktonic
niches, all need to be minimized to resolve the risk of
invasive infection. A clinically healing wound has
“healthy” granulation tissue and a viable epithelial edge,
and is visibly clean, even when minimal biofilm persists.
Likewise in burn injuries, using light and electron micros-
copy, it has been demonstrated that biofilms may develop
as early as 7 days at the site of an escharotomy, which
suggests that early and complete excision is warranted.77
(The importance of debridement is in maintaining a
healthy wound bed, and is discussed further in section
“Mechanical Debridement”).
In vitro data suggest that there is a window of opportu-
nity for biofilm prevention following debridement of up to
24 hours when biofilms, to the degree that they are at all
susceptible, tend to have increased response to systemic
antibiotics, and topical antiseptics in particular.58 How-
ever, this is dependent on the microorganisms present and
the host factors, and assumes that maintenance debride-
ment is undertaken at dressing changes. This strategy
should be used until the wound bed is visibly clean, dis-
playing healthy granulation tissue, and/or on a healing
trajectory.
Guidelines for chronic wound biofilms Schultz et al.
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In general, systemic antibiotics and topical antiseptics
are of limited use in managing biofilm for several reasons
as, generally, bacteria in biofilms are highly tolerant of
broad classes of antibiotics and antiseptics. First, cationic
antiseptics have limited penetration due to binding with
anionic components in the EPS and second, bacteria in the
biofilm enter a dormant-like phenotype in which there is
no or little activity for antibiotics to disrupt.78,79 In the
presence of acute infection (or with masked secondary
signs of infection), antibiotics should be used under the
guidance of antibiotic and antiseptic stewardship guide-
lines.80 These state that stewardship is defined as
“coordinated interventions designed to improve and mea-
sure the appropriate use of [antibiotic] agents by promot-
ing the selection of the optimal [antibiotic] drug regimen
including dosing, duration of therapy, and route of admin-
istration.”81 The major value of systemic antibiotics is in
controlling acute local infection, systemic infection, and
sepsis, rather than directly treating the biofilm itself. Anti-
biotics should be narrow-spectrum for known sensitivities
whenever possible and broad-spectrum when there is life-
threatening infection/sepsis, and given usually by a paren-
teral route. Topical antiseptics may also help to prevent
spread/reseeding of a biofilm after debridement, and their
use is discussed more fully in the Topical antiseptics sec-
tion. For a summary of comparative mechanisms of action
of topical antimicrobials in disrupting biofilm formation,
see Snyder et al. (2017).82
Mechanical debridement
(1) Wound bed preparation (tissue, infection/inflamma-
tion, moisture balance, and edge of wound) is an impor-
tant part of biofilm treatment [strong agreement, mean
4.2, SD 0.83].
(2) Surgical or conservative sharp wound debridement
(CSWD) are effective ways to help remove biofilm
from the surface of an open wound in which biofilm is
suspected [strong agreement, mean 4.5, SD 0.71].
(3) Currently, there is limited evidence for other types
of debridement that include enzymatic debridement
[weak agreement, mean 3.7, SD 0.82] or ultrasonic
debridement [weak agreement, mean 3.8, SD 0.92].
(4) Debridement does not necessarily remove all biofilm
[strong agreement, mean 4.6, SD 0.52].
(5) The removal of visible slough and debris in a
wound is not sufficient to entirely remove all biofilm
[strong agreement, mean 4.8, SD 0.63].
Key statement: (6) Biofilms can reform rapidly;
repeated debridement alone is unlikely to prevent bio-
film regrowth; however, appropriate topical antiseptic
application within this time-dependent window can
suppress biofilm reformation [strong agreement, mean
4.0, SD 0.67].
Evidence summary
Paying attention to each of the four core components of
wound bed preparation is a practical guide to optimize
healing of open, chronic wounds.71–75 These principles
emphasize the importance of maintaining a healthy wound
bed, with debridement of necrotic tissue including biofilm,
wound cleansing, and antimicrobial therapy being key
components of this goal.65,71,83
In vivo, regrowth of mature biofilms can occur within 72
hours, but early presence of biofilms can be detected within 24
hours after debridement.58 Repeated debridement (much like
how regular tooth brushing helps control biofilm) might be
able to suppress biofilm development and keep it in a weak-
ened state so that both systemic antibiotic and topical antiseptic
therapy, moisture management, and host immunity might have
a better chance of suppressing the risk of infection.76 CSWD
and physical removal/disruption and prevention of re-formation
of biofilms are critical to promoting healing; this is supported
by several national and international guidelines.3,11,84 The use
of several modalities at one time (e.g., ultrasonic wound
debridement together with CSWD using a scalpel or loop
curette) may increase success; however, this has only been
demonstrated in vitro.85 Further clinical work is required to
assess ultrasound for debridement and killing of bacteria asso-
ciated with tissue and exudate.7
Although debridement can be very effective in helping
to reduce bioburden and biofilms, it cannot remove all
microorganisms present in the wound; in fact, one study
suggests a reduction of only 1–2 logs.86 Debridement
must, therefore, be used in conjunction with topical anti-
septic dressings and lavage or therapeutic irrigation to
enhance further microbial reductions through killing of
microbial cells and to suppress regrowth of the biofilm.87
Removal of visible slough and debris, while useful as it
might contain superficial biofilm, does not represent the
total biofilm, as much will reside deeper within the
wound.51 In summary, the concepts of wound bed prepara-
tion and biofilm-based wound care emphasize the impor-
tance of combining effective wound debridement with
treatments to reduce inflammation/infection by appropriate
antimicrobial intervention after debridement.
Topical antiseptics
(1) In circumstances where CSWD is not possible,
appropriate topical antiseptics offer an effective inter-
vention against wound biofilms [weak agreement, mean
3.9, SD 0.74].
(2) There are several reasons why some antibiotic and
antiseptic treatments fail. These include:
(2.1) The slow metabolic rate of biofilm bacteria in
biofilm [strong agreement, mean 4.5, SD 0.85].
(2.2) Interactions with the EPS components [strong
agreement, mean 4.0, SD 0.94].
(3) Topical antiseptics that are effective antibiofilm
treatments should:
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(3.1) Reach biofilm-embedded bacteria in an active
form [strong agreement, mean 4.0, SD 1.05].
(3.2) Provide a high and sustained active level (due
to the higher Minimum Biofilm Eradication Concen-
tration [MBEC] required against biofilms) [strong
agreement, mean 4.3, SD 0.82].
Key statement: (3.3) Have strong antibiofilm
effects in appropriate in vitro test models against
mature biofilms [strong agreement, mean 4.4,
SD 0.7].
(4) Topical appropriate antiseptics are recommended as
first-line therapy in stalled wounds [full panel agree-
ment at final meeting].
Evidence summary
Biofilms are extremely tolerant to multiple forms of antimi-
crobial treatment. There are now several in-depth reviews
and scientific studies detailing the complexity of biofilm
tolerance, and we will not expand upon these, but summa-
rize the key concepts attributed to biofilm tolerance. These
include: the protective layer of the EPS, which slows or
inhibits the diffusion of an antibiotic into the bio-
film,11,21,88–90 and indicates that other protective mecha-
nisms of biofilms must be at play; the concept of the
“micro-niche,” in which the altered chemical gradients of
nutrients, oxygen, pH, and metabolites may affect both an
antibiotic and or the bacteria residing in that area and retard
the action of an antibiotic60,91,92; and the role of a very
small population of specific cells within a biofilm (persister
cells) that develop broad resistance against antibiotics and
antiseptics.27,93–95 The persister phenotype, dormancy, or
the nutrient limitation theory can lead to inactivity of cells
within the biofilm.93,96 Due to dormant micro-niches within
biofilm, antibiotics are less effective.97 This has been
highlighted by several in vitro biofilm models that have elu-
cidated that bacteria in biofilms can withstand antibiotic
concentrations considerably higher than their planktonic
counterparts.97,98 However, even with optimal kinetics and
high minimal biofilm inhibitory concentration (MBIC), it is
not possible to reach the concentrations needed to kill all
the bacteria in biofilms in humans.99,100
The role of topical antiseptics in chronic nonhealing
wounds has been extensively reviewed, resulting in a con-
sensus document issued by the European Wound Manage-
ment Association.12
Antibiotics work on specific sites in replicating (meta-
bolically active) bacterial cells, whereas topical antiseptics
generally inactivate bacteria by interaction through multi-
ple target sites. Therefore, the use of antiseptics is less
reliant on cell division for them to be effective. If the
main tolerance mechanism is dormancy, and the mode of
action of an antibiotic, or antiseptic, is to interfere with a
cellular process, then ability to disrupt or penetrate the bio-
film will not provide much of a therapeutic advantage.
Appropriately used topical antiseptics are more effective
after disruption of the biofilm by debridement,101,102 and
have the additional advantage of being much less likely to
induce resistance compared with antibiotic treatment.103
By delaying the re-formation of biofilm, topical antiseptics
may reduce the risk of infection and the need for antibiot-
ics, which is important in consideration of prevention of
the development of antibiotic resistance.
Screening antibiotics and antiseptics
Key statement: (1) In vitro biofilm methods with clini-
cally relevant test conditions are useful to screen treat-
ments for their antibiofilm efficacy [strong agreement,
mean 4.5, SD 0.71].
(2) Test methodologies should reproducibly recover bio-
film bacteria from the test system [strong agreement,
mean 4.6, SD 0.70].
(3) Clinically relevant in vitro methodologies should:
(3.1) Use media containing serum or blood proteins
[strong agreement, mean 4.4, SD 0.7].
(3.2) Use mature biofilms appropriate to laboratory
design [strong agreement, mean 4.1, SD 1.0].
(3.3) Include single and polymicrobial cultures rele-
vant to the indication of interest [strong agreement,
mean 4.4, SD 0.7].
(3.4) Show measurable reduction in biofilm bacterial
count over a clinically relevant time [strong agree-
ment, mean 4.2, SD 0.63].
(4) The use of ATP-based measurement is not consid-
ered an important way to determine biofilm viability
and antibiofilm efficacy [full panel agreement at final
meeting].
Evidence summary
In vitro experiments offer a rapid method, and in some
cases, may be the only way, to screen antibiofilm treat-
ments.104 Models may also provide an initial measurement
of how potentially effective products may work under
controlled conditions, which is important given the high
complexity of in vivo human studies. As one example, a
rabbit ear model has been validated and used to study
numerous facets of wound healing.5–7 However, in vitro
models may not accurately represent in vivo conditions.99
It is important that in vitro biofilm models reproduce the
chronic wound environment using clinically relevant test
conditions. For example, serum or blood proteins may
diminish the activity of antiseptics in particular, and test-
ing in the presence of such materials is important. The use
of immature biofilms when testing antibiotics and antisep-
tics in laboratory experiments can lead to false success in
relation to treatment efficacy. When reproduced with more
mature biofilms, as would be expected in chronic wounds,
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the results may not show the same efficacy.4 Better stan-
dard methods need to be developed that are relevant to the
clinical indication and environment and also type of treat-
ment being tested.105
The properties of biofilms can also be influenced by the
surfaces on which they are grown.106,107 An in vitro sys-
tem that more closely resembles an in vivo surface, regard-
less of its specific design, would be desirable, but is not
absolutely necessary as long as the method can be vali-
dated. Tissue-based surfaces could conceivably allow a
more natural progression of biofilm growth to occur, with
potential implications on the 3D structure of a biofilm,
which may be extremely important for function. However,
bacteria in a chronic wound are rarely directly in contact
with fresh, “healthy” tissue, so the benefits of a tissue-
based growth surface are uncertain.
Test methodologies should reproducibly recover biofilm
bacteria from the test system. To obtain a useful sample,
some type of validated physical disruption may be neces-
sary prior to analysis, such as sonication or repeated vor-
texing. This depends on the specific analysis method being
used. Disruption is not necessary for molecular identifica-
tion methods, as many of the DNA/RNA isolation methods
already contain digestion or disruption techniques required
for analysis. Molecular approaches can provide data from
effectiveness studies by looking at microbial load, and
diversity and presence of pathogens, in addition to micro-
scopic methods that can look at spatial organization pre-
and posttreatment, or the semiquantitative approach to
visualizing biofilms through SEM or CLSM.
Any in vitro method should ideally show a measurable
reduction in biofilm bacterial count over a clinically rele-
vant time. It seems reasonable to conclude that greater log
reductions are preferable, but aiming for specific log
reductions may be a “planktonic concept,” and not readily
transferable to biofilms. In addition, quantitative criteria
for infection of acute wounds may not be appropriate for
nonhealing wounds.9 It must be remembered that such
high reduction in vitro may not necessarily translate to the
clinical situation, and that treatments must balance antibi-
otic and antiseptic activity with minimal cell toxicity.
Adenosine triphosphate (ATP) has been used in labora-
tory situations to assess viability where a pure bacterial
species is involved, but application to clinical settings is
limited. In an actual wound, there are typically mixed pop-
ulations of viable bacteria and wound cells also containing
ATP, and dormant but viable bacteria producing less ATP.
Therefore, bacterial killing cannot be assured simply by
measuring ATP levels.
Levels of evidence when choosing antibiofilm
treatments
Key statement: (1) Randomized controlled trials
(RCTs) and comparative clinical evidence of antibiofilm
treatment should be used to support clinical guidelines,
protocols, and treatment choices. However, in the
absence of RCT-level data, antibiofilm interventions
should be supported by RCT evidence of the broader
impact on wound healing [strong agreement, mean 4.2,
SD 0.79].
(2) Evidence from in vitro screening [strong agreement,
mean 4.0, SD 0.94] and animal studies [strong agree-
ment, mean 4.1, SD 0.74] of antibiofilm effect is impor-
tant for clinicians to consider when choosing treatments,
although clinical evidence is required to validate these
findings.
(3) Clinical evidence from noncomparative studies and
case studies is important but cannot allow for clear con-
clusions to be drawn on efficacy of a product [full
panel agreement at final meeting].
Evidence summary
Many wound treatment decisions for chronic wound man-
agement are not supported by strong evidence, and this is
particularly relevant in biofilm control. Currently, the bulk
of research has been conducted in vitro, with questionable
relevance due to factors such as the use of “immature or
young” biofilms. Validated laboratory models exist,5–7 but
they may not always be easily extrapolated to the clinical
situation. Basic clinical evaluations are lacking and, where
available, are commonly tested in small patient numbers
without controls or clear interventions. Thus, the degree to
which recommended treatment algorithms improve wound
healing outcomes over standard care remains to be estab-
lished. One of the current issues with animal models is that
they tend to be short-term without underlying comorbidities,
and do not necessarily replicate a low-grade chronic infec-
tion. Acknowledging these differences in immune function
and response to infection in people can help bridge the gap
between in vitro tests and clinical situations.35–38
Significant advances in the understanding of how anti-
biofilm agents work can be made with the appropriate use
of in vitro systems, particularly when study designs
account for relevance to a clinical scenario. If an in vitro
study is able to identify an effective antibiofilm strategy,
this can form the premise for undertaking more costly in
vivo clinical studies. This, in turn, may help bridge the
gap from bench to bedside, providing a powerful basis to
aid alterations to clinical decisions. Furthermore, evidence
from in vivo studies should explore whether antibiofilm
agents are effective in killing/dispersing/reducing bacteria
associated with biofilm compared to controls. Ideally, data
should be obtained from clinical RCTs, but in vivo RCTs
in this field are hard to undertake and expensive, and het-
erogeneity among trials is high.
CONCLUSION
This consensus document aligns existing scientific knowl-
edge on biofilms, much of which is from in vitro studies
and animal models (as opposed to human clinical trials) or
the wider understanding of biofilms in other human dis-
eases, with expert opinion on best practices for the treat-
ment of biofilms and management of the chronic wounds
with which they are associated.
The consensus statements are shaped by panel members’
scientific and clinical experience, accompanied by data
from published scientific communications. The panel
hopes that this document provides clarity on areas of
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biofilm identification and management, and can be used as
a tool for clinicians seeking to gain greater understanding
of biofilms and how they relate to translating research to
best clinical practice. The panel’s activity represents an
important next step in working toward improving out-
comes for patients with nonhealing wounds, and, in the
future, it is our hope that these consensus statements will
be supported by appropriate clinical studies.
Some algorithms have been published to try to capture
the key signs and symptoms of biofilm presence.15,16 How-
ever, there is a need for more clinical validation of such
algorithms before they become truly accepted broadly into
clinical practice. It is beyond the scope of this consensus
document, as well as the existing evidence, to recommend
specific products or therapeutics. Ideally, future studies
will confirm that following specific algorithm-guided treat-
ment results in improved clinical outcomes over standard
care, and the panel hopes to prepare another document that
will focus on these issues.
Based on the panel’s assessment of data and recommen-
dations, a major concept that has emerged is the need for
strong initial combination treatment (i.e., the most effec-
tive debridement technique in conjunction with the most
effective antibiofilm treatment) to rapidly and effectively
reduce biofilm levels within wounds, and subsequently
reduce inflammation, reactive oxygen species, and protease
activities. This early intervention should be followed by
stepped-down treatment as shown in Figure 2. The result
will be more rapid healing of wounds, which reduces cost,
as well as risk of amputation, and could lead to improved
patient quality of life.
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